Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Shares Issued (2017 - 2025)

Cytokinetics (CYTK) has disclosed Shares Issued for 15 consecutive years, with -$14.0 million as the latest value for Q4 2025.

  • Quarterly Shares Issued changed N/A to -$14.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$14.0 million through Dec 2025, changed N/A year-over-year, with the annual reading at $36.0 million for FY2025, 32.14% down from the prior year.
  • Shares Issued for Q4 2025 was -$14.0 million at Cytokinetics, down from $29.5 million in the prior quarter.
  • The five-year high for Shares Issued was $29.5 million in Q1 2024, with the low at -$14.0 million in Q4 2025.
  • Average Shares Issued over 5 years is $3.2 million, with a median of $3.6 million recorded in 2021.
  • The sharpest move saw Shares Issued plummeted 443.47% in 2023, then surged 732.59% in 2024.
  • Over 5 years, Shares Issued stood at $12.4 million in 2021, then crashed by 70.94% to $3.6 million in 2022, then tumbled by 443.47% to -$12.4 million in 2023, then skyrocketed by 338.97% to $29.5 million in 2024, then tumbled by 147.48% to -$14.0 million in 2025.
  • According to Business Quant data, Shares Issued over the past three periods came in at -$14.0 million, $29.5 million, and -$12.4 million for Q4 2025, Q1 2024, and Q4 2023 respectively.